Tech Company Financing Transactions

Zavante Therapeutics Funding Round

Zavante Therapeutics, based in San Diego, received $45 million in funding from Frazier Healthcare Partners, Longitude Capital Management and Aisling Capital.

Transaction Overview

Company Name
Zavante Therapeutics
Announced On
3/30/2016
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors

Frazier Healthcare Partners (Lead Investor) (Patrick Heron)

Longitude Capital Management (Lead Investor) (David Hirsch)

Aisling Capital (Andrew Schiff)

Proceeds Purpose
The company has closed a $45 million Series A financing, consisting of $35 million from new investors and $10 million from the conversion of outstanding convertible notes. Proceeds from the financing will be used for the development of the Company's lead product candidate, ZTI-01 (fosfomycin for injection), an injectable antibiotic with a differentiated mechanism of action designed for use in the hospital setting. In the second quarter of 2016, Zavante plans to initiate the ZEUS Study, a single pivotal clinical trial for ZTI-01, a first-in-class broad spectrum IV antibiotic under development to treat multidrug resistant (MDR) pathogens.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12670 High Bluff Dr.
San Diego, CA 92130
USA
Phone
Undisclosed
Website
www.zavante.com
Email Address
[email protected]
Overview
We are passionately committed to our mission to improve patients' lives by identifying, developing and commercializing novel therapeutics addressing significant unmet medical needs in the hospital setting.
Profile
Zavante Therapeutics LinkedIn Company Profile
Social Media
Zavante Therapeutics Company Twitter Account
Company News
Zavante Therapeutics News
Facebook
Zavante Therapeutics on Facebook
YouTube
Zavante Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Ted Schroeder
  Ted Schroeder LinkedIn Profile  Ted Schroeder Twitter Account  Ted Schroeder News  Ted Schroeder on Facebook
Chief Financial Officer
Richard Vincent
  Richard Vincent LinkedIn Profile  Richard Vincent Twitter Account  Richard Vincent News  Richard Vincent on Facebook
Chief Operating Officer
Kevin Finney
  Kevin Finney LinkedIn Profile  Kevin Finney Twitter Account  Kevin Finney News  Kevin Finney on Facebook
Chief Scientific Officer
EJ Ellis-Grosse
  EJ Ellis-Grosse LinkedIn Profile  EJ Ellis-Grosse Twitter Account  EJ Ellis-Grosse News  EJ Ellis-Grosse on Facebook
VP - Manufacturing
Robert DiVasto
  Robert DiVasto LinkedIn Profile  Robert DiVasto Twitter Account  Robert DiVasto News  Robert DiVasto on Facebook
VP - Operations
David Skarinsky
  David Skarinsky LinkedIn Profile  David Skarinsky Twitter Account  David Skarinsky News  David Skarinsky on Facebook
VP - Regulatory Affairs
Kristina Haeckl
  Kristina Haeckl LinkedIn Profile  Kristina Haeckl Twitter Account  Kristina Haeckl News  Kristina Haeckl on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/30/2016: Beamr venture capital transaction
Next: 3/30/2016: Figtree Financing venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.